感染

订阅

MedSci主页 / 所有栏目 / 感染

COVID-19继发的急性肺损伤：FDA批准RLS-0071进行临床试验

2020-07-29 Allan MedSci原创

急性肺损伤Covid-19RLS-0071
关注

制药公司ReAlta今天宣布，美国FDA已接受其RLS-0071的研究性新药（IND）申请，用于治疗COVID-19继发的急性肺损伤。

制药公司ReAlta今天宣布，美国FDA已接受其RLS-0071的研究性新药（IND）申请，用于治疗COVID-19继发的急性肺损伤。RLS-0071是一种工程化多肽，具有双重靶向机制，旨在通过直接与免疫细胞相互作用以调节其激活，同时可减少过度炎症来抑制补体和抗炎免疫反应。RLS-0071最初被开发用于治疗COVID-19相关的急性肺损伤和儿童缺氧缺血性脑病（HIE）。

在COVID-19患者中，病毒感染可导致不受控制的炎症和急性肺损伤。在临床前疾病模型中，RLS-0071具有调节补体、中性粒细胞和细胞因子激活并减少导致急性肺损伤的关键炎症途径的能力。

ReAlta首席执行官Ulrich Thienel博士表示：“COVID-19对患者的影响可能是极端的，包括威胁生命的肺部疾病。RLS-0071可能解决COVID-19继发的急性肺损伤等问题”。急性肺损伤是各种直接和间接致伤因素导致的肺泡上皮细胞及毛细血管内皮细胞损伤，造成弥漫性肺间质及肺泡水肿，导致的急性低氧性呼吸功能不全。

 

原始出处：

https://www.firstwordpharma.com/node/1744281?tsid=4

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1839856, encodeId=c3d7183985624, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu May 27 14:16:52 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724522, encodeId=7f771e2452251, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Thu Mar 11 11:16:52 CST 2021, time=2021-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395407, encodeId=8b43139540e56, content=<a href='/topic/show?id=d051523897d' target=_blank style='color:#2F92EE;'>#急性肺损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52389, encryptionId=d051523897d, topicName=急性肺损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Jul 31 01:16:52 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398019, encodeId=4e6a139801924, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Jul 31 01:16:52 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503332, encodeId=cfb115033329c, content=<a href='/topic/show?id=67a7821250e' target=_blank style='color:#2F92EE;'>#肺损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82125, encryptionId=67a7821250e, topicName=肺损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05329610584, createdName=tastas, createdTime=Fri Jul 31 01:16:52 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805028, encodeId=3c0c80502875, content=这是急性肺损伤的福英, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eef2099827, createdName=1801f6448em, createdTime=Wed Jul 29 10:25:26 CST 2020, time=2020-07-29, status=1, ipAttribution=)]
    2021-05-27 bugit

    #FDA批准#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1839856, encodeId=c3d7183985624, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu May 27 14:16:52 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724522, encodeId=7f771e2452251, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Thu Mar 11 11:16:52 CST 2021, time=2021-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395407, encodeId=8b43139540e56, content=<a href='/topic/show?id=d051523897d' target=_blank style='color:#2F92EE;'>#急性肺损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52389, encryptionId=d051523897d, topicName=急性肺损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Jul 31 01:16:52 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398019, encodeId=4e6a139801924, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Jul 31 01:16:52 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503332, encodeId=cfb115033329c, content=<a href='/topic/show?id=67a7821250e' target=_blank style='color:#2F92EE;'>#肺损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82125, encryptionId=67a7821250e, topicName=肺损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05329610584, createdName=tastas, createdTime=Fri Jul 31 01:16:52 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805028, encodeId=3c0c80502875, content=这是急性肺损伤的福英, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eef2099827, createdName=1801f6448em, createdTime=Wed Jul 29 10:25:26 CST 2020, time=2020-07-29, status=1, ipAttribution=)]
    2021-03-11 feifers

    #继发#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1839856, encodeId=c3d7183985624, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu May 27 14:16:52 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724522, encodeId=7f771e2452251, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Thu Mar 11 11:16:52 CST 2021, time=2021-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395407, encodeId=8b43139540e56, content=<a href='/topic/show?id=d051523897d' target=_blank style='color:#2F92EE;'>#急性肺损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52389, encryptionId=d051523897d, topicName=急性肺损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Jul 31 01:16:52 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398019, encodeId=4e6a139801924, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Jul 31 01:16:52 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503332, encodeId=cfb115033329c, content=<a href='/topic/show?id=67a7821250e' target=_blank style='color:#2F92EE;'>#肺损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82125, encryptionId=67a7821250e, topicName=肺损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05329610584, createdName=tastas, createdTime=Fri Jul 31 01:16:52 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805028, encodeId=3c0c80502875, content=这是急性肺损伤的福英, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eef2099827, createdName=1801f6448em, createdTime=Wed Jul 29 10:25:26 CST 2020, time=2020-07-29, status=1, ipAttribution=)]
    2020-07-31 仁医06

    #急性肺损伤#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1839856, encodeId=c3d7183985624, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu May 27 14:16:52 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724522, encodeId=7f771e2452251, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Thu Mar 11 11:16:52 CST 2021, time=2021-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395407, encodeId=8b43139540e56, content=<a href='/topic/show?id=d051523897d' target=_blank style='color:#2F92EE;'>#急性肺损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52389, encryptionId=d051523897d, topicName=急性肺损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Jul 31 01:16:52 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398019, encodeId=4e6a139801924, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Jul 31 01:16:52 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503332, encodeId=cfb115033329c, content=<a href='/topic/show?id=67a7821250e' target=_blank style='color:#2F92EE;'>#肺损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82125, encryptionId=67a7821250e, topicName=肺损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05329610584, createdName=tastas, createdTime=Fri Jul 31 01:16:52 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805028, encodeId=3c0c80502875, content=这是急性肺损伤的福英, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eef2099827, createdName=1801f6448em, createdTime=Wed Jul 29 10:25:26 CST 2020, time=2020-07-29, status=1, ipAttribution=)]
    2020-07-31 ms3046638856685384

    #损伤#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1839856, encodeId=c3d7183985624, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu May 27 14:16:52 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724522, encodeId=7f771e2452251, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Thu Mar 11 11:16:52 CST 2021, time=2021-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395407, encodeId=8b43139540e56, content=<a href='/topic/show?id=d051523897d' target=_blank style='color:#2F92EE;'>#急性肺损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52389, encryptionId=d051523897d, topicName=急性肺损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Jul 31 01:16:52 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398019, encodeId=4e6a139801924, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Jul 31 01:16:52 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503332, encodeId=cfb115033329c, content=<a href='/topic/show?id=67a7821250e' target=_blank style='color:#2F92EE;'>#肺损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82125, encryptionId=67a7821250e, topicName=肺损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05329610584, createdName=tastas, createdTime=Fri Jul 31 01:16:52 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805028, encodeId=3c0c80502875, content=这是急性肺损伤的福英, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eef2099827, createdName=1801f6448em, createdTime=Wed Jul 29 10:25:26 CST 2020, time=2020-07-29, status=1, ipAttribution=)]
    2020-07-31 tastas

    #肺损伤#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1839856, encodeId=c3d7183985624, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Thu May 27 14:16:52 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724522, encodeId=7f771e2452251, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Thu Mar 11 11:16:52 CST 2021, time=2021-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395407, encodeId=8b43139540e56, content=<a href='/topic/show?id=d051523897d' target=_blank style='color:#2F92EE;'>#急性肺损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52389, encryptionId=d051523897d, topicName=急性肺损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Jul 31 01:16:52 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398019, encodeId=4e6a139801924, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Fri Jul 31 01:16:52 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503332, encodeId=cfb115033329c, content=<a href='/topic/show?id=67a7821250e' target=_blank style='color:#2F92EE;'>#肺损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82125, encryptionId=67a7821250e, topicName=肺损伤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=05329610584, createdName=tastas, createdTime=Fri Jul 31 01:16:52 CST 2020, time=2020-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805028, encodeId=3c0c80502875, content=这是急性肺损伤的福英, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eef2099827, createdName=1801f6448em, createdTime=Wed Jul 29 10:25:26 CST 2020, time=2020-07-29, status=1, ipAttribution=)]
    2020-07-29 1801f6448em

    这是急性肺损伤的福英

    0

相关资讯

ANG-3777治疗COVID-19急性肺损伤：已启动II期临床试验

生物制药公司Angion宣布，已在巴西启动了一项随机安慰剂对照的II期临床试验，以研究ANG-3777联合标准疗法治疗COVID-19肺炎相关急性肺损伤的有效性。

Plos Pathog：酰基羧酸水解酶促进脂多糖诱导的急性肺损伤的消退

我们报告了AOAH以前不了解的促进LPS或革兰氏阴性细菌诱导的肺损伤的消退的作用。除了许多其他预分解机制，我们的研究表明，灭活MAMP分子对于从MAMP诱导的肺损伤中恢复是至关重要的。促进组织中LPS和其他MAMP分子降解的干预可促进炎症的消除。

Am J Physiol Lung Cell Mol Physiol：自噬抑制剂3-甲基腺嘌呤可以保护急性肺损伤时内皮细胞屏障功能障碍。

近期的研究涉及自噬在许多包括肺部的疾病中的作用。然而，自噬在内皮细胞（EC）屏障功能障碍及其在急性肺损伤（ALI）背景下与EC屏障功能障碍的相关性仍然不确定。

Algernon正在探索将Ifenprodil用作COVID-19冠状病毒的新型疗法，小鼠实验中该药物具有显着降低急性肺损伤的作用

Algernon Pharmaceuticals公司近日宣布，正在探索使用NP-120（Ifenprodil）作为冠状病毒COVID-19新型治疗方法的潜力。

Cell Death Diff：iASPP可通过抑制细胞铁死亡来减轻肠道局部缺血/再灌注诱发的急性肺损伤

急性肺损伤（ALI）是一种危及生命的严重疾病，在患有多种疾病的患者中，其发病率及死亡率非常高。

Biochem Biophys Res Commun：右美托咪啶通过抑制肺成纤维细胞缝隙连接功能，保护脂多糖诱导的细胞凋亡

背景与目的：α2-肾上腺素受体激动剂右美托咪定对急性肺损伤（ALI）具有保护作用，但其机制还有很多尚不清楚。

拓展阅读

Front Med：COVID-19住院患者Casirivimab/imdevimab失败预测评分的开发和验证

Casirivimab和imdevimab是两种非竞争性、高亲和力的人IgG1抗COVID-19单克隆抗体，它们特异性结合COVID-19病毒刺突糖蛋白的受体结合域，从而阻断病毒进入宿主细胞。

Biomedicines：2型糖尿病住院患者COVID-19的长期预后

在T2D合并COVID-19患者中，随访观察到住院死亡率、卒中和心血管住院率增加。

Cureus：2型糖尿病状态、糖尿病并发症严重程度指数评分及其与COVID-19严重程度的关系

与非糖尿病患者相比，我们样本中的糖尿病患者发生COVID-19不良临床结果和住院死亡率的几率更高。

Lancet Infect Dis：口服VV116用于治疗轻中度COVID-19成人患者的有效性和安全性评价

目前，治疗COVID-19的医疗需求仍未得到满足，新型抗病毒药物-VV116可用于治疗轻中度COVID-19成人患者，能够显著缩短临床症状持续时间，与其他药物较少发生药物间相互作用，且安全性良好。

论文解读｜Yihua Wang教授团队新研究揭示了揭示COVID-19对肺癌治疗和研究的深远影响

该文章揭示了此次大流行对肺癌治疗、临床试验、研究活动的影响。

JAMA Intern Med：COVID-19相关急性肾损伤与长期肾脏结果

与患有其他疾病相关AKI的患者相比，COVID-AKI住院幸存者的MAKE发生率、长期肾功能下降和死亡率均显著较低。